Agreement will utilise RetinAI’s IT solutions and artificial intelligence tools to support projects in ophthalmology
News
Winners shine bright at PharmaTimes Awards
Meet the winners of the 2020 PharmaTimes Marketer of the Year, Communications Awards and Sales Awards
Roche reveals new bispecific antibody data in blood cancers
‘Encouraging’ data for investigational candidates across a range of blood cancers
NICE backs AZ’ Calquence for chronic lymphocytic leukaemia
The recommendations are positive for a select population of patients with CLL
Two medicines accepted for use by NHS Scotland
Medicines for blood cancer and a rare muscle disorder will be made available for NHS patients
CR UK makes further cuts in COVID’s wake
The charity is slashing £45 million from its research budget
World first as UK launches COVID-19 vaccination programme
A 90 year-old woman in Coventry has become the first person in the UK to be given the vaccine
Calquence shows long-term efficacy and tolerability in MCL
Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with AstraZeneca’s Calquence remained progression free for a median of 22 months
Research highlights benefit of telemedicine for stroke treatment
Around one in five stroke patients could go undiagnosed with the tests currently used by paramedics
Valneva fast-tracks paediatric development of Lyme disease vaccine
Company plans phase II study launch in first quarter of 2021
UK launch for Vagirux
The drug is administered intravaginally as a local oestrogen therapy for treatment of vaginal atrophy due to oestrogen deficiency.
Janssen seeks EU approval for twice-yearly schizophrenia treatment
Extension application is based on results from Janssen’s Route 6 study
Genentech’s Gavreto scores US approval for RET thyroid cancer
Precision therapy is designed to selectively target RET alterations
RPS in discussions with government to improve patient access to medicines
Follows joint letter calling for pharmacists to be able make minor prescription changes
Janssen eyes US approval for EGFR-targeting NSCLC therapy
Bispecific antibody targets EGFR and MET mutated tumours
